| Title |
Asparaginase pharmacology: challenges still to be faced
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, February 2017
|
| DOI | 10.1007/s00280-016-3236-y |
| Pubmed ID | |
| Authors |
Claudia Lanvers-Kaminsky |
| Abstract |
The benefits of asparaginase (ASNASE) in the treatment of ALL and NHL are indisputable and new ASNASE preparations are under clinical development to overcome limitations of the actual ASNASE therapy, especially immunogenicity. Apart from ALL and NHL further indications of ASNASE are preclinically and clinically evaluated. We reviewed ASNASE literature and especially focused on the mechanism of action, on biomarker, which determine ASNASE sensitivity and resistance, and on ASNASE pharmacodynamics in vivo. More than 40 years after the clinical introduction of ASNASE its mechanism of action is yet not fully understood. Studies on asparagine synthetase (ASNS) as biomarker for ASNASE resistance are contradictory and complicated by methodological obstacles. The role of glutamine hydrolysis for ASNASE efficacy is still debated, other mechanisms are possibly not yet identified. In addition, individual pharmacokinetic/-dynamic relationships cannot be properly addressed because of methodological limitations. More sophisticated preclinical models and suitable methods for monitoring of ASNASE pharmacodynamics are urgently needed (1) to understand the mechanism of action, (2) to establish valid biomarkers for ASNASE sensitivity and resistance, (3) to evaluate the pharmacokinetics/-dynamics of ASNASEs in individual patients, and (4) to compare the bioequivalence of clinically established, as well as new ASNASE preparations. |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 1% |
| Russia | 1 | 1% |
| Unknown | 87 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 18% |
| Student > Master | 14 | 16% |
| Student > Ph. D. Student | 11 | 12% |
| Researcher | 9 | 10% |
| Student > Postgraduate | 5 | 6% |
| Other | 12 | 13% |
| Unknown | 22 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 31 | 35% |
| Medicine and Dentistry | 14 | 16% |
| Agricultural and Biological Sciences | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Chemistry | 3 | 3% |
| Other | 5 | 6% |
| Unknown | 25 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2020.
All research outputs
#8,759,452
of 25,837,817 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#735
of 2,584 outputs
Outputs of similar age
#154,760
of 438,525 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#9
of 29 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,584 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,525 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.